CELC Historical PE Ratio Notes

— Celcuity Inc. (CELC) is a clinical-stage biotechnology company pioneering precision diagnostics & targeted therapies for cancer, driven by the goal of matching individual patients with the treatments most likely to benefit them. The company's core technology, CELsignia, evaluates live tumor cell signaling activity to identify novel patient groups and supports development of new drugs, most notably its lead investigational therapy gedatolisib, for breast cancer and other indications. Because Celcuity is still pre-revenue & focused on research, early-stage clinical trials, and pipeline development, it has historically generated minimal or negative earnings, resulting in high or undefined PE ratios. Investors reviewing its historical PE ratios should be aware that standard valuation metrics like PE are less meaningful for biotech firms that have not yet achieved commercial viability; PE spikes or periods of N/A reflect both the volatility of early-stage biotech stock prices and the absence of meaningful earnings. The stock market's valuation of CELC over time has been influenced less by current profits, and more by clinical trial progress, regulatory milestones, & overall optimism in the drug development pipeline—factors that make its PE ratio history distinct from more mature, profit-generating companies.

On this page we presented the Celcuity Historical PE Ratio information for Celcuity' stock. The average CELC historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CELC historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CELC historical PE result, against the recent PE: when this page was posted on 3/6/2026, the most recent closing price for CELC had been 115.00, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CELC or any other given stock, valuation analysis for CELC can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Celcuity PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CELC. Thanks for visiting, and the next time you need to research CELC Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.